print

James Corsetti, M.D., Ph.D.

Associate Professor of Pathology and Laboratory Medicine

Clinical Chemistry
Regulation of Hepatic Metabolism of Lipoproteins

URMC Labs
601 Elmwood Ave., Rm G-1572
Rochester, NY 14642-8608
Tel: (585) 275-4907
Fax: (585) 273-3003

James_Corsetti@urmc.rochester.edu

Dr. Corsetti is Medical Director of the Clinical Trials Laboratory and Associate Director of the Automated Laboratory and Protein Laboratory.

Qualifications

M.D., Brown University 1982
Ph.D., Physical Chemistry, Harvard University 1980
Resident in Pathology, University of Rochester Medical Center 1982-86
Board Certification (AP/CP), American Board of Pathology 1987

Research Overview

My current research interests focus on studies of cardiovascular disease risk in human populations using non-traditional statistical approaches, especially as related to risk associations involving novel biomarkers as well as genetic markers.  Underlying our approach is the hypothesis that particular blood and genetic risk markers are most efficacious in particular patient subgroups and that, in general, different patient subgroups have different markers of risk.  As such, we have recently developed a 3-dimensional graphical exploratory data analysis technique that we call “outcome event mapping” that allows identification of high-risk patient subgroups not constrained by traditional rectilinear approaches to subgroup identification and allowing subgroup identification even in unexpected regions of risk parameter domains.  With it, we have demonstrated a high-risk subgroup in post-MI patients based upon high levels of serum C-reactive protein (CRP) and total cholesterol.  Interestingly, we have shown the counter-intuitive result that within this subgroup elevated high-density lipoprotein (HDL) cholesterol, the so-called “good cholesterol”, is a risk factor for recurrent events, a finding that we ascribe to transformation of the usual anti-inflammatory HDL into pro-inflammatory HDL.  We have also been able to adapt outcome event mapping to delineate subgroup-specific risk in association with single-nucleotide polymorphism (SNP) variants.  For example, we have shown that a variant of a SNP in the p22phox subunit of NAD(P)H oxidase (an enzyme playing a critical role in generation of reactive oxygen species and thus potentially in the transformation of HDL) is associated with risk along with elevated HDL in this subgroup.  We plan future studies to delineate mechanisms involved in elevated HDL-associated risk using outcome event mapping with additional genetic markers together with advanced statistical techniques to elucidate causal pathways; and to fully characterize the physico-chemical nature of changes at the molecular level in HDL mediating transformation of HDL from anti-inflammatory to pro-inflammatory in nature.

Publications

Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Block RC, and Sparks CE.  Lp(a) and Risk of Recurrent Cardiac Events in Obese Postinfarction Patients.  Obesity.  2008 Dec;16(12):2717-2722.

Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, and Sparks CE.  Plasminogen Activator Inhibitor-1 Polymorphism (4G/5G) Predicts Recurrence in Non-Hyperlipidemic Postinfarction Patients.  Arteriosclerosis, Thrombosis, and Vascular Biology.  2008 Mar;28(3):548-554.

Corsetti JP, Ryan D, Moss AJ, Zareba W, and Sparks CE.  NAD(P)H Oxidase Polymorphism (C242T) and High HDL Cholesterol Associate with Recurrent Coronary Events in Post infarction Patients.  Atherosclerosis.  2008;196:461-468.

Multiple co-authors, and Corsetti JP.  Collaborative Meta-Analysis of Individual Participant Data from Observational Studies of Lp-PLA2 and Cardiovascular Diseases.  European Journal of Cardiovascular Prevention and Rehabilitation.  2007 Feb;14(1):3-11.

Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, and Sparks CE.  Glycoprotein Ibα Polymorphism (T145M), Elevated Lipoprotein-Associated Phospholipase A2, and Hypertriglyceridemia Predict risk for Recurrent Coronary Events in Diabetic Postinfarction Patients. Diabetes.  2007 May;56(5):1429-1435.

Corsetti JP, Rainwater DL, Moss AJ, Zareba W, and Sparks CE.  High Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients.  Clinical Chemistry.  2006 Jul;52(7):1331-1338.

Corsetti JP, Zareba W, Moss AJ, Rainwater DL, and Sparks CE.  Elevated HDL Is a Risk Factor for Recurrent Coronary Events in a Subgroup of Non-Diabetic Postinfarction Patients with Hypercholesterolemia and Inflammation.  Atherosclerosis.  2006 Jul;187(1):191-197.

Corsetti JP, Zareba W, Moss AJ, and Sparks CE.  Serum Glucose and Triglyceride Determine Hig-Risk Subgroups in Non-Diabetic Postinfarction Patients.  Atherosclerosis.  2005 Dec;183(2):293-300.

Corsetti JP, Zareba W, Moss AJ, and Sparks CE.  Apolipoprotein B Determines Risk for Recurrent Coronary Events in Postinfarction Patients with Metabolic Syndrome.  Atherosclerosis.  2004 Dec;177(2):367-373.

Corsetti JP, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rainwater DL, and Sparks CE.  Metabolic Syndrome Best Defines the Multivariate Distribution of Blood Variables in Postinfarction Patients.  Atherosclerosis.  2003 Dec;171(2):351-358.